Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

Caplin, Martyn E., Pavel, Marianne, Ćwikła, Jaroslaw B., Phan, Alexandria T., Raderer, Markus, Sedlácková, Eva, Cadiot, Guillaume, Wolin, Edward M., Capdevila, Jaume, Wall, Lucy, Rindi, Guido, Langley, Alison, Martinez, Séverine, Blumberg, Joëlle and Ruszniewski, Philippe 2014. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine 371 (3) , pp. 224-233. 10.1056/NEJMoa1316158

Full text not available from this repository.


We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced, well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor–positive neuroendocrine tumors of grade 1 or 2 (a tumor proliferation index [on staining for the Ki-67 antigen] of <10%) and documented disease-progression status. The tumors originated in the pancreas, midgut, or hindgut or were of unknown origin. Patients were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide (Autogel [known in the United States as Depot], Ipsen) at a dose of 120 mg (101 patients) or placebo (103 patients) once every 28 days for 96 weeks. The primary end point was progression-free survival, defined as the time to disease progression (according to the Response Evaluation Criteria in Solid Tumors, version 1.0) or death. Secondary end points included overall survival, quality of life (assessed with the European Organization for Research and Treatment of Cancer questionnaires QLQ-C30 and QLQ-GI.NET21), and safety.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: Massachusetts Medical Society
ISSN: 0028-4793
Date of Acceptance: 2014
Last Modified: 31 May 2019 13:45

Citation Data

Cited 342 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item